306 related articles for article (PubMed ID: 15570574)
1. Post-treatment emergent adverse events in depressed patients following treatment with milnacipran and paroxetine.
Vandel P; Sechter D; Weiller E; Pezous N; Cabanac F; Tournoux A; Panconi E
Hum Psychopharmacol; 2004 Dec; 19(8):585-6. PubMed ID: 15570574
[No Abstract] [Full Text] [Related]
2. A comparative study of milnacipran and paroxetine in outpatients with major depression.
Sechter D; Vandel P; Weiller E; Pezous N; Cabanac F; Tournoux A;
J Affect Disord; 2004 Dec; 83(2-3):233-6. PubMed ID: 15555719
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of milnacipran, fluvoxamine and paroxetine for depression, especially in gender.
Morishita S; Arita S
Eur Psychiatry; 2003 Dec; 18(8):418-20. PubMed ID: 14680720
[No Abstract] [Full Text] [Related]
4. Comparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression: a summary of clinical trial results.
Kasper S; Pletan Y; Solles A; Tournoux A
Int Clin Psychopharmacol; 1996 Sep; 11 Suppl 4():35-9. PubMed ID: 8923125
[TBL] [Abstract][Full Text] [Related]
5. Effects of paroxetine or milnacipran on serum brain-derived neurotrophic factor in depressed patients.
Yoshimura R; Mitoma M; Sugita A; Hori H; Okamoto T; Umene W; Ueda N; Nakamura J
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1034-7. PubMed ID: 17459550
[TBL] [Abstract][Full Text] [Related]
6. Milnacipran and selective serotonin reuptake inhibitors in major depression.
Lopez-Ibor J; Guelfi JD; Pletan Y; Tournoux A; Prost JF
Int Clin Psychopharmacol; 1996 Sep; 11 Suppl 4():41-6. PubMed ID: 8923126
[TBL] [Abstract][Full Text] [Related]
7. Double-blind study of the efficacy and safety of milnacipran and imipramine in elderly patients with major depressive episode.
Tignol J; Pujol-Domenech J; Chartres JP; Léger JM; Plétan Y; Tonelli I; Tournoux A; Pezous N
Acta Psychiatr Scand; 1998 Feb; 97(2):157-65. PubMed ID: 9517912
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of milnacipran: an overview.
Montgomery SA; Prost JF; Solles A; Briley M
Int Clin Psychopharmacol; 1996 Sep; 11 Suppl 4():47-51. PubMed ID: 8923127
[TBL] [Abstract][Full Text] [Related]
9. Milnacipran for fibromyalgia.
Dempsey J
Issues Emerg Health Technol; 2008 Feb; (114):1-4. PubMed ID: 18354855
[TBL] [Abstract][Full Text] [Related]
10. Effects of milnacipran and paroxetine on overactive bladder due to neurologic diseases: a urodynamic assessment.
Sakakibara R; Ito T; Uchiyama T; Awa Y; Yamaguchi C; Hattori T
Urol Int; 2008; 81(3):335-9. PubMed ID: 18931554
[TBL] [Abstract][Full Text] [Related]
11. [Serotonin-noradrenaline reuptake inhibitors(SNRIs)].
Ishigooka J
Nihon Rinsho; 2001 Aug; 59(8):1523-9. PubMed ID: 11519152
[TBL] [Abstract][Full Text] [Related]
12. Levomilnacipran (Fetzima) a new SNRI for depression.
Med Lett Drugs Ther; 2013 Dec; 55(1432):101-2. PubMed ID: 24419243
[No Abstract] [Full Text] [Related]
13. Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability.
Puech A; Montgomery SA; Prost JF; Solles A; Briley M
Int Clin Psychopharmacol; 1997 Mar; 12(2):99-108. PubMed ID: 9219045
[TBL] [Abstract][Full Text] [Related]
14. Clinical efficacy of milnacipran: placebo-controlled trials.
Lecrubier Y; Pletan Y; Solles A; Tournoux A; Magne V
Int Clin Psychopharmacol; 1996 Sep; 11 Suppl 4():29-33. PubMed ID: 8923124
[TBL] [Abstract][Full Text] [Related]
15. A double-blind six months comparative study of milnacipran and clomipramine in major depressive disorder.
Steen A; Den Boer JA
Int Clin Psychopharmacol; 1997 Sep; 12(5):269-81. PubMed ID: 9466161
[TBL] [Abstract][Full Text] [Related]
16. Possible interaction between milnacipran and warfarin potassium.
Sawamura J; Kozaki K; Mochizuki S; Ishigooka J
J Clin Pharmacol; 2012 May; 52(5):780-1. PubMed ID: 22539653
[No Abstract] [Full Text] [Related]
17. Raynaud's syndrome in a patient treated with milnacipran.
Bourgade B; Jonville-Béra AP; Le Garé C; Ferquel D; Autret-Leca E
Ann Pharmacother; 1999 Sep; 33(9):1009-10. PubMed ID: 10492510
[No Abstract] [Full Text] [Related]
18. Efficacy of levomilnacipran extended-release in improving functional impairment associated with major depressive disorder: pooled analyses of five double-blind, placebo-controlled trials.
Sambunaris A; Gommoll C; Chen C; Greenberg WM
Int Clin Psychopharmacol; 2014 Jul; 29(4):197-205. PubMed ID: 24667487
[TBL] [Abstract][Full Text] [Related]
19. Levomilnacipran: a newly approved drug for treatment of major depressive disorder.
Mago R; Mahajan R; Thase ME
Expert Rev Clin Pharmacol; 2014 Mar; 7(2):137-45. PubMed ID: 24524592
[TBL] [Abstract][Full Text] [Related]
20. Clinical potential of milnacipran, a serotonin and norepinephrine reuptake inhibitor, in pain.
Leo RJ; Brooks VL
Curr Opin Investig Drugs; 2006 Jul; 7(7):637-42. PubMed ID: 16869117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
